Telomerase activity in benign and malignant thyroid diseases

Kazuo Yashima, Frank Vuitch, Adi F. Gazdar, Thomas J. Fahey

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background. Telomerase, an enzyme associated with cellular immortality, is expressed by most malignant cells and is inactive in most normal somatic cells, with the exception of proliferative stem cells, male germ cells, and activated lymphocytes. The measurement of telomerase activity in clinically obtained tissue samples may provide useful information as both a diagnostic and prognostic marker. In this study, we sought to determine whether telomerase activity might prove helpful in the assessment of benign and malignant thyroid tumors. Methods. A modified, semiquantitative polymerase chain reaction-based telomeric repeat amplification protocol assay was used for detection of telomerase activity in 59 samples obtained at thyroidectomy, including 15 thyroid cancers, 22 benign thyroid diseases, and 22 adjacent normal thyroid tissues. Results. Four of 13 differentiated thyroid carcinomas (30%) and 2 of 2 medullary carcinomas (100%) expressed telomerase activity. Unexpectedly, we also detected activity in 3 of 22 (14%) adjacent normal thyroid tissues and 6 of 22 (28%) benign thyroid diseases. Pathologic review of the telomerase-positive benign specimens revealed that many contained extensive lymphoid infiltrates with germinal centers (six of nine, 67%), as did two of four telomerase-positive papillary carcinomas. Conclusions. In contradistinction to other epithelial carcinomas, telomerase does not appear to be frequently reactivated in differentiated thyroid carcinomas.

Original languageEnglish (US)
Pages (from-to)1141-1146
Number of pages6
JournalSurgery
Volume122
Issue number6
DOIs
StatePublished - Dec 1997

Fingerprint

Telomerase
Thyroid Diseases
Thyroid Neoplasms
Thyroid Gland
Medullary Carcinoma
Germinal Center
Papillary Carcinoma
Thyroidectomy
Germ Cells
Stem Cells
Lymphocytes
Carcinoma
Polymerase Chain Reaction
Enzymes

ASJC Scopus subject areas

  • Surgery

Cite this

Yashima, K., Vuitch, F., Gazdar, A. F., & Fahey, T. J. (1997). Telomerase activity in benign and malignant thyroid diseases. Surgery, 122(6), 1141-1146. https://doi.org/10.1016/S0039-6060(97)90220-8

Telomerase activity in benign and malignant thyroid diseases. / Yashima, Kazuo; Vuitch, Frank; Gazdar, Adi F.; Fahey, Thomas J.

In: Surgery, Vol. 122, No. 6, 12.1997, p. 1141-1146.

Research output: Contribution to journalArticle

Yashima, K, Vuitch, F, Gazdar, AF & Fahey, TJ 1997, 'Telomerase activity in benign and malignant thyroid diseases', Surgery, vol. 122, no. 6, pp. 1141-1146. https://doi.org/10.1016/S0039-6060(97)90220-8
Yashima, Kazuo ; Vuitch, Frank ; Gazdar, Adi F. ; Fahey, Thomas J. / Telomerase activity in benign and malignant thyroid diseases. In: Surgery. 1997 ; Vol. 122, No. 6. pp. 1141-1146.
@article{4e95307c26244ecca9c1b13528107a32,
title = "Telomerase activity in benign and malignant thyroid diseases",
abstract = "Background. Telomerase, an enzyme associated with cellular immortality, is expressed by most malignant cells and is inactive in most normal somatic cells, with the exception of proliferative stem cells, male germ cells, and activated lymphocytes. The measurement of telomerase activity in clinically obtained tissue samples may provide useful information as both a diagnostic and prognostic marker. In this study, we sought to determine whether telomerase activity might prove helpful in the assessment of benign and malignant thyroid tumors. Methods. A modified, semiquantitative polymerase chain reaction-based telomeric repeat amplification protocol assay was used for detection of telomerase activity in 59 samples obtained at thyroidectomy, including 15 thyroid cancers, 22 benign thyroid diseases, and 22 adjacent normal thyroid tissues. Results. Four of 13 differentiated thyroid carcinomas (30{\%}) and 2 of 2 medullary carcinomas (100{\%}) expressed telomerase activity. Unexpectedly, we also detected activity in 3 of 22 (14{\%}) adjacent normal thyroid tissues and 6 of 22 (28{\%}) benign thyroid diseases. Pathologic review of the telomerase-positive benign specimens revealed that many contained extensive lymphoid infiltrates with germinal centers (six of nine, 67{\%}), as did two of four telomerase-positive papillary carcinomas. Conclusions. In contradistinction to other epithelial carcinomas, telomerase does not appear to be frequently reactivated in differentiated thyroid carcinomas.",
author = "Kazuo Yashima and Frank Vuitch and Gazdar, {Adi F.} and Fahey, {Thomas J.}",
year = "1997",
month = "12",
doi = "10.1016/S0039-6060(97)90220-8",
language = "English (US)",
volume = "122",
pages = "1141--1146",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Telomerase activity in benign and malignant thyroid diseases

AU - Yashima, Kazuo

AU - Vuitch, Frank

AU - Gazdar, Adi F.

AU - Fahey, Thomas J.

PY - 1997/12

Y1 - 1997/12

N2 - Background. Telomerase, an enzyme associated with cellular immortality, is expressed by most malignant cells and is inactive in most normal somatic cells, with the exception of proliferative stem cells, male germ cells, and activated lymphocytes. The measurement of telomerase activity in clinically obtained tissue samples may provide useful information as both a diagnostic and prognostic marker. In this study, we sought to determine whether telomerase activity might prove helpful in the assessment of benign and malignant thyroid tumors. Methods. A modified, semiquantitative polymerase chain reaction-based telomeric repeat amplification protocol assay was used for detection of telomerase activity in 59 samples obtained at thyroidectomy, including 15 thyroid cancers, 22 benign thyroid diseases, and 22 adjacent normal thyroid tissues. Results. Four of 13 differentiated thyroid carcinomas (30%) and 2 of 2 medullary carcinomas (100%) expressed telomerase activity. Unexpectedly, we also detected activity in 3 of 22 (14%) adjacent normal thyroid tissues and 6 of 22 (28%) benign thyroid diseases. Pathologic review of the telomerase-positive benign specimens revealed that many contained extensive lymphoid infiltrates with germinal centers (six of nine, 67%), as did two of four telomerase-positive papillary carcinomas. Conclusions. In contradistinction to other epithelial carcinomas, telomerase does not appear to be frequently reactivated in differentiated thyroid carcinomas.

AB - Background. Telomerase, an enzyme associated with cellular immortality, is expressed by most malignant cells and is inactive in most normal somatic cells, with the exception of proliferative stem cells, male germ cells, and activated lymphocytes. The measurement of telomerase activity in clinically obtained tissue samples may provide useful information as both a diagnostic and prognostic marker. In this study, we sought to determine whether telomerase activity might prove helpful in the assessment of benign and malignant thyroid tumors. Methods. A modified, semiquantitative polymerase chain reaction-based telomeric repeat amplification protocol assay was used for detection of telomerase activity in 59 samples obtained at thyroidectomy, including 15 thyroid cancers, 22 benign thyroid diseases, and 22 adjacent normal thyroid tissues. Results. Four of 13 differentiated thyroid carcinomas (30%) and 2 of 2 medullary carcinomas (100%) expressed telomerase activity. Unexpectedly, we also detected activity in 3 of 22 (14%) adjacent normal thyroid tissues and 6 of 22 (28%) benign thyroid diseases. Pathologic review of the telomerase-positive benign specimens revealed that many contained extensive lymphoid infiltrates with germinal centers (six of nine, 67%), as did two of four telomerase-positive papillary carcinomas. Conclusions. In contradistinction to other epithelial carcinomas, telomerase does not appear to be frequently reactivated in differentiated thyroid carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0031443577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031443577&partnerID=8YFLogxK

U2 - 10.1016/S0039-6060(97)90220-8

DO - 10.1016/S0039-6060(97)90220-8

M3 - Article

C2 - 9426431

AN - SCOPUS:0031443577

VL - 122

SP - 1141

EP - 1146

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -